[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nakhia Impex LLC\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":249},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,54,83,113,139,165,196,223],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":4},"100638786","efficacy-and-safety-of-ha35-gel-nighttime-occlusive-application-for-tmd-pain-100638786",false,"NCT07584642","Efficacy and Safety of HA35 Gel Nighttime Occlusive Application for TMD Pain","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate Efficacy and Safety of Nighttime Occlusive 10% 35 kDa Hyaluronan (HA35) Gel for Temporomandibular Joint Disorder (TMD) Pain and Muscle Over-Tension","HA35-TMJ","Inclusion Criteria:\n\n* Age 18-60 years, male or female\n* Clinically diagnosed with TMD with TMJ pain and\u002For muscle over-tension\n* Baseline TMJ pain NRS score ≥3\n* History of bruxism or jaw clenching\n* Ability to complete NRS assessments independently\n* Signed written informed consent\n\nExclusion Criteria:\n\n* TMJ treatment (medication, physical therapy, injection) within 2 weeks\n* Topical analgesic\u002Fanti-inflammatory use within 24 hours\n* Skin damage, allergy, or infection in the TMJ application area\n* Severe systemic disease (cardiovascular, diabetes, autoimmune)\n* Known hypersensitivity to hyaluronan or gel components\n* Pregnant or lactating women","ALL","18 Years","60 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of nighttime occlusive application of 10% high-concentration 35 kDa hyaluronan (HA35) gel in subjects with temporomandibular joint disorder (TMD). Eligible participants will apply HA35 gel to the TMJ area nightly under occlusive conditions for 8-12 hours. The primary objectives are to assess rapid pain relief and muscle over-tension reduction at 60 seconds and 12 hours after application. Safety and local tolerability will be evaluated throughout the study period. This is a minimal-risk, non-pharmacological, non-invasive intervention.",[28,29,30,31,32],"Temporomandibular Joint Disorders","TMD","Temporomandibular Joint Pain","Jaw Muscle Over-Tension","Bruxism",[34,35,36,37,29,30,38,39,40,41],"Hyaluronan","35 kDa Hyaluronan","Nighttime Occlusive","TMJ","Muscle Over-Tension","Analgesia","Non-invasive Treatment","Pilot Clinical Study","NOT_YET_RECRUITING","2026-05-07",{"date":45,"type":46},"2026-05-13","ACTUAL",{"date":48,"type":22},"2026-05-20",{"date":50,"type":22},"2026-07-20",{"name":52,"class":53},"Nakhia Impex LLC","INDUSTRY",{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":65,"conditions":66,"keywords":72,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100639272","efficacy-and-safety-of-ha35-gel-for-post-dental-gingival-pain-and-swelling-100639272","NCT07584655","Efficacy and Safety of HA35 Gel for Post-Dental Gingival Pain and Swelling","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate Efficacy and Safety of Topical 10% 35 kDa Hyaluronan (HA35) Gel for Post-Dental Gingival Pain and Swelling","HA35","Inclusion Criteria:\n\n* Age 18-65 years, male or female\n* Experienced gingival pain and swelling within 12 hours after dental procedures\n* Baseline gingival pain NRS score ≥2\n* Able to independently complete pain and swelling assessments\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Severe periodontitis, uncontrolled diabetes, or immune dysfunction\n* Long-term use of analgesics or anti-inflammatory drugs\n* Known hypersensitivity to hyaluronan or gel components\n* Oral infection, ulceration, or severe mucosal injury at the application site\n* Pregnant or lactating women","65 Years",{"count":21,"type":22},[25],"This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of 10% high-concentration 35 kDa hyaluronan (HA35) gel delivered via gel-soaked cotton balls in patients with gingival pain and swelling after dental procedures. Eligible participants will gently chew and retain the gel-soaked cotton balls on the affected area for 30 minutes. The primary objectives are to assess changes in gingival pain and swelling at 1, 30, and 60 minutes after application. Safety and local oral tolerability will be evaluated throughout the observation period. This is a minimal-risk, non-pharmacological, non-invasive intervention.",[67,68,69,70,71],"Post-Dental Gingival Pain","Gingival Swelling","Postoperative Oral Pain","Dental Procedure-Related Discomfort","Periodontal Inflammation",[34,35,60,73,74,68,75,39,76,41],"Topical Gel","Gingival Pain","Dental Postoperative Care","Anti-Inflammation",{"date":45,"type":46},{"date":79,"type":22},"2026-06-01",{"date":81,"type":22},"2026-08-01",{"name":52,"class":53},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":91,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":92,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":102,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":111,"leadSponsor":112,"locationsCount":4},"100637390","efficacy-and-safety-of-high-dose-oral-35-kda-hyaluronan-for-aesthetic-improvement-100637390","NCT07583108","Efficacy and Safety of High-Dose Oral 35 kDa Hyaluronan for Aesthetic Improvement","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate Efficacy and Safety of High-Dose Oral 35 kDa Hyaluronan (HA35) in Subjects Seeking Facial and Body Aesthetic Improvement","HA35-ORAL","Inclusion Criteria:\n\n* Age 18-60 years, male or female\n* Seeking non-invasive improvement of facial\u002Fbody appearance\n* Presenting with facial fullness, double chin, subcutaneous fat accumulation, facial erythema, or dull skin\n* Ability to complete VAS assessments and study logs\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Aesthetic\u002Fweight loss treatments (injection, laser, liposuction, diet drugs) within 4 weeks\n* Significant weight change (\\>3 kg) within 3 months\n* Uncontrolled systemic disease (diabetes, hypertension, etc.)\n* Known hypersensitivity to hyaluronan\n* Pregnant or lactating women\n* Participation in another clinical trial within 30 days",true,{"count":21,"type":22},[25],"This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of high-dose oral 70 kDa hyaluronan (HA35) for aesthetic improvement. Eligible participants will receive 5 g oral HA35 once daily on an empty stomach for 40 consecutive days. The primary objectives are to assess changes in facial and body subcutaneous fullness, inflammatory erythema, facial vitality, and body weight. Safety, gastrointestinal tolerability, and additional exploratory outcomes will be evaluated throughout the intervention period. This is a minimal-risk, oral, non-pharmacological supportive care intervention.",[96,97,98,99,100,101],"Facial Subcutaneous Fullness","Subcutaneous Fat Accumulation","Facial Inflammatory Erythema","Dull Skin","Facial Vitality Impairment","Body Weight Management",[34,35,60,103,104,105,106,107,108,41],"Oral Administration","Subcutaneous Fat Reduction","Facial Erythema","Facial Vitality","Body Weight","Non-invasive Aesthetic",{"date":45,"type":46},{"date":48,"type":22},{"date":50,"type":22},{"name":52,"class":53},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":121,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":123,"conditions":124,"keywords":129,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":134,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":138,"locationsCount":4},"100637469","efficacy-and-safety-of-overnight-occlusive-ha35-gel-for-facial-aesthetic-improvement-100637469","NCT07584811","Efficacy and Safety of Overnight Occlusive HA35 Gel for Facial Aesthetic Improvement","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate Efficacy and Safety of Overnight Occlusive Topical 10% 35 kDa Hyaluronan (HA35) Gel for Facial Subcutaneous Fat Appearance, Erythema, Skin Radiance, and Pore Condition","HA35-FACIAL","Inclusion Criteria:\n\n* Age 18-60 years, male or female\n* Seeking non-invasive improvement of facial appearance\n* Presenting with at least one of: facial subcutaneous fat accumulation, facial erythema, skin dullness, nasal alar pore enlargement\n* Baseline NRS score ≥2 for at least one target parameter\n* Ability to complete self-assessments\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Facial aesthetic treatments (injection, laser, fat reduction, peeling) within 2 weeks\n* Active facial dermatitis, infection, or open wounds\n* Known hypersensitivity to hyaluronan or gel components\n* Pregnant or lactating women\n* Severe systemic disease or uncontrolled medical condition",{"count":21,"type":22},[25],"This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of overnight occlusive topical application of 10% high-concentration 35 kDa hyaluronan (HA35) gel for facial aesthetic improvement. Eligible participants will receive overnight occlusive application once every 2 days for a total of 5 treatments over 10 days. The primary objectives are to assess changes in facial subcutaneous fat appearance, inflammatory erythema, skin radiance, and nasal alar pore enlargement after 1 and 5 applications. Safety and local tolerability will be evaluated throughout the study period. This is a minimal-risk, non-pharmacological, non-invasive aesthetic intervention.",[125,105,126,127,128],"Facial Subcutaneous Fat","Skin Dullness","Nasal Alar Pore Enlargement","Facial Aesthetic Improvement",[34,35,60,130,73,131,105,132,133,108,41],"Overnight Occlusive","Facial Fat","Skin Radiance","Pore Improvement",{"date":45,"type":46},{"date":136,"type":22},"2026-05-01",{"date":50,"type":22},{"name":52,"class":53},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":149,"conditions":150,"keywords":155,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":163,"leadSponsor":164,"locationsCount":4},"100639359","efficacy-and-safety-of-ha35-gel-for-mild-gingival-recession-and-periodontal-inflammation-100639359","NCT07577258","Efficacy and Safety of HA35 Gel for Mild Gingival Recession and Periodontal Inflammation","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate Efficacy and Safety of Topical 10% 35 kDa Hyaluronan (HA35) Gel for Mild Gingival Recession and Chronic Periodontal Inflammation","HA35-PERI","Inclusion Criteria:\n\n* Age 18-60 years, male or female\n* Clinically diagnosed with mild gingival recession (Miller Class I or II)\n* Chronic gingival pain, redness, swelling, or brushing-induced bleeding\n* Ability to complete self-assessments and comply with 42-day intervention\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Severe periodontitis, tooth mobility, or alveolar bone loss\n* Uncontrolled diabetes or immune dysfunction\n* Use of prescription periodontal medications within 2 weeks\n* Known hypersensitivity to hyaluronan or gel components\n* Oral infection, ulceration, or severe mucosal injury\n* Pregnant or lactating women",{"count":21,"type":22},[25],"This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel in subjects with mild gingival recession and chronic periodontal inflammation. Eligible participants will apply the HA35 gel topically to the gingival and tooth surfaces twice daily for 42 consecutive days. The primary objectives are to assess changes in gingival recession, chronic gingival or radicular pain, gingival redness and swelling, and brushing-induced bleeding. Safety and local oral tolerability will be evaluated throughout the treatment period. This is a minimal-risk, non-pharmacological, non-invasive oral care intervention.",[151,71,152,153,154],"Mild Gingival Recession","Chronic Gingival Pain","Gingival Redness and Swelling","Gingival Bleeding",[34,35,60,156,157,74,154,158,159,41],"Gingival Recession","Periodontal Disease","Gingival Repair","Oral Care",{"date":161,"type":46},"2026-05-12",{"date":79,"type":22},{"date":81,"type":22},{"name":52,"class":53},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":62,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":174,"briefSummary":175,"conditions":176,"keywords":184,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":4},"100637488","efficacy-and-safety-of-ha35-gel-for-ultra-rapid-skin-pruritus-relief-100637488","NCT07580911","Efficacy and Safety of HA35 Gel for Ultra-Rapid Skin Pruritus Relief","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate Efficacy and Safety of Topical 10% 35 kDa Hyaluronan (HA35) Gel for Ultra-Rapid Relief of Diverse Etiology Skin Pruritus","HA35-ITCH","Inclusion Criteria:\n\n* Age 18-65 years, male or female\n* Moderate-to-severe skin pruritus (NRS ≥6) due to eczema, neurodermatitis, insect bites, urticaria, or postoperative wound itch\n* Able to understand and complete NRS assessments independently\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Topical corticosteroid\u002Fantihistamine use within 2 weeks\n* Infected, broken, or exudative skin lesions at the application site\n* Known hypersensitivity to hyaluronan or gel components\n* Severe systemic disease or immune dysfunction\n* Pregnant or lactating women",{"count":21,"type":22},[25],"This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel for ultra-rapid relief of moderate-to-severe skin pruritus from diverse etiologies (eczema, neurodermatitis, insect bites, urticaria, postoperative wound itch). Eligible participants will receive a single topical application of HA35 gel. The primary objective is to assess pruritus relief at 10 seconds, 45 minutes, 8 hours, 12 hours, and 24 hours post-application. Safety and local skin tolerability will be evaluated throughout the observation period. This is a minimal-risk, non-pharmacological, non-invasive intervention.",[177,178,179,180,181,182,183],"Skin Pruritus","Itch","Eczema Itch","Neurodermatitis","Insect Bite Itch","Urticaria","Postoperative Wound Pruritus",[34,35,60,73,177,185,186,187,188,41],"Itch Relief","Ultra-Rapid Relief","Anti-Pruritus","Non-Steroidal","2026-05-05",{"date":161,"type":46},{"date":192,"type":22},"2026-06-20",{"date":194,"type":22},"2026-08-20",{"name":52,"class":53},{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":23,"phases":206,"briefSummary":207,"conditions":208,"keywords":214,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":220,"leadSponsor":222,"locationsCount":4},"100636768","efficacy-and-safety-of-high-concentration-35-kda-hyaluronan-gel-for-herpes-zoster-associated-pain-100636768","NCT07569978","Efficacy and Safety of High-Concentration 35 kDa Hyaluronan Gel for Herpes Zoster-Associated Pain","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate the Efficacy and Safety of Topical 10% High-Concentration 35 kDa Hyaluronan (HA35) Gel in Subjects With Herpes Zoster-Associated Pain","HA35-HZ","Inclusion Criteria:\n\n* Age 18-85 years, male or female\n* Clinically diagnosed with herpes zoster-associated pain (acute ZAP or PHN)\n* Baseline pain NRS score ≥5\n* Ability to understand and complete NRS assessments\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Acute bacterial skin infection at the application site\n* Use of topical analgesics or antiviral therapy within 24 hours\n* Systemic analgesic use within 6 hours\n* Known hypersensitivity to hyaluronan or gel components\n* Pregnant or lactating women\n* Severe systemic disease or malignant tumor","85 Years",{"count":21,"type":22},[25],"This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel in subjects with herpes zoster-associated pain (ZAP). Eligible participants will receive a single topical application of the study gel. The primary objective is to assess rapid pain reduction within 2 minutes and 24hours after application. Secondary objectives include evaluation of analgesic duration, local tolerability, erythema improvement, and overall safety throughout the observation period. This is a minimal-risk, non-pharmacological supportive care intervention.",[209,210,211,212,213],"Herpes Zoster","Zoster-Associated Pain","Postherpetic Neuralgia","Neuropathic Pain","Acute Pain",[34,35,60,73,209,215,211,212,39,216,41],"Zoster Pain","Non-pharmacological Intervention",{"date":218,"type":46},"2026-05-08",{"date":136,"type":22},{"date":221,"type":22},"2026-07-10",{"name":52,"class":53},{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":60,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":230,"enrollmentInfo":231,"targetDuration":4,"studyType":23,"phases":232,"briefSummary":233,"conditions":234,"keywords":240,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":246,"leadSponsor":248,"locationsCount":4},"100636658","efficacy-and-safety-of-high-concentration-35-kda-hyaluronan-gel-for-chronic-nasopharyngitis-100636658","NCT07568548","Efficacy and Safety of High-Concentration 35 kDa Hyaluronan Gel for Chronic Nasopharyngitis","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate Efficacy and Safety of Topical 10% 35 kDa Hyaluronan (HA35) Gel for Ultra-Rapid Relief of Skin Pruritus","Inclusion Criteria:\n\n* Age 18-80 years, male or female\n* Clinically diagnosed with chronic rhinitis and chronic pharyngitis for ≥3 months\n* Baseline nasopharyngeal discomfort NRS score ≥4 points\n* Baseline posterior pharyngeal discomfort NRS score ≥4 points\n* Voluntary participation and signed written informed consent\n* Ability to complete symptom assessment independently\n\nExclusion Criteria:\n\n* Acute upper respiratory tract infection within 2 weeks\n* Use of antihistamines, intranasal corticosteroids, decongestants, or other nasal medications within 2 weeks prior to screening\n* History of nasal\u002Fsinus surgery within 6 months\n* Known hypersensitivity to hyaluronan or any gel ingredients\n* Pregnant or lactating women\n* Severe systemic diseases or malignant tumors","80 Years",{"count":21,"type":22},[25],"This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of nasopharyngeal administration of 13.6% high-concentration 35 kDa hyaluronan (HA35) care gel in subjects with chronic rhinitis and chronic pharyngitis. Eligible participants will receive the study gel twice daily for 10 consecutive days. The primary objectives are to assess rapid changes in nasopharyngeal discomfort, posterior pharyngeal discomfort, and nasal obstruction within 30 minutes after the first administration. Secondary objectives include evaluation of overall symptom improvement at day 10, changes in subjective mental clarity, and safety and tolerability throughout the treatment period. This is a minimal-risk, non-pharmacological supportive care intervention.",[235,236,237,238,239],"Chronic Rhinitis","Chronic Pharyngitis","Nasopharyngitis","Posterior Pharyngeal Inflammation","Nasal Obstruction",[34,35,60,241,235,236,242,243,216,41],"Nasopharyngeal Care","Nasal Congestion","Pharyngeal Discomfort",{"date":218,"type":46},{"date":136,"type":22},{"date":247,"type":22},"2026-07-01",{"name":52,"class":53},""]